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Abstract In quantifying the beneficial effect of dietary
interventions in healthy subjects, nutrition research meets a
number of new challenges. Inter individual variation in
biomarker values often is larger than the effect related to the
intervention. Healthy subjects have a remarkable capacity
to maintain homeostasis, both through direct metabolic
regulation, metabolic compensation of altered diets, and
effective defence and repair mechanisms in oxidative and
inflammatory stress. Processes involved in these regulatory
activities essentially different from processes involved in
early onset of diet related diseases. So, new concepts and
approaches are needed to better quantify the subtle effects
possibly achieved by dietary interventions in healthy
subjects. Apart from quantification of the genotype and food
intake (these are discussed in separate reviews in this ser-
ies), four major areas of innovation are discussed: the
biomarker profile concept, perturbation of homeostasis
combined with omics analysis, imaging, modelling and
fluxes. All of these areas contribute to a better under-
standing and quantification of the nutritional phenotype.
Keywords Nutritional phenotype  Homeostasis 
Perturbation  Imaging
Health status quantification
Nutrition research is focused on the impact of foods on
health. Traditionally, biomarkers related to (the onset of)
disease or organ damage were used to quantify the effects.
With the emerging drive to focus on the exploitation of food
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for health optimization and disease prevention, it becomes
necessary to quantify phenotypic changes which are very
close to, or even within the range of the healthy state. This
imposes major challenges, because diet-induced changes in
phenotype usually are very small and hard to quantify and the
system rapidly re-establishes normal homeostasis. More-
over, these changes usually are smaller than the inter-
individual variations within a healthy phenotype [21, 62].
Thus, accurate quantification of the effect of nutrients on
health is a major bottleneck for progress. This is true for
genetically defined sub-groups as well as for nutrition
research in general. The research area of nutrigenomics has
made enormous progress in recent years, applying omics
technologies in the diet-health relationship [10, 19, 34, 52].
Yet, this has primarily focused on unravelling mechanisms
and biomarker profiles. The aim of this review is to consider
the different aspects of‘ quantification of health effects and
provide specific recommendations. The term ‘nutritional
phenotype’ has been introduced with this purpose in mind
[72], and is defined as a set of integrated genetic, transcrip-
tomic, proteomic, metabolomic, functional and behavioral
data, which provide the basis for assessment of human
nutritional status and health. In a limited number of cases the
phenotype is strongly and straightforwardly correlated to
genotype (e.g. phenylalanine ketonuria), but the nutrition—
genotype—phenotype relation is relevant even in cases
where no straight forward translation from genotype to
phenotype is possible [11]. Recent emerging knowledge on
the epigenetic variation of this genotype-phenotype rela-
tionship allows a more precise understanding of the plasticity
of our phenotype and the impact of nutrition on this.
Complex and subtly regulated processes such as glucose
homeostasis are full of genotypic differences. Nevertheless,
homeostasis is maintained by ‘individual’ adaptation of a
multitude of nutritionally regulated processes [15]. Daily
dietary intake influences nutritional status through, for
example, the postprandial response to lipids, proteins or car-
bohydrates [31, 43] and nutritional phenotype stems from
lifetime’s exposure, beginning with fetal life [5, 42, 64] and
stretching into old age [2]. There are marked changes as an
individual goes through life, which emphasize their own
peculiar and individual adjustments. Certain phenotypic
aspects change continuously while others progress more
gradually, leading to modification of health status. Develop-
ment of disease phenotypes thus reflects interaction between a
‘sensitive genotype’ and nutrient-derived metabolic stressors,
which influence a multitude of molecular mechanisms.
Bottlenecks
In addition to the genetic variation as discussed in the first
review of this series [67] and inaccurate food intake
assessment, there are a variety of issues interfering with the
quantification of the subtle health effects related to diet
including (also see Fig. 1):
• Intra- and inter-individual variation caused by con-
founding’ factors, which mask significant change.
• Absence of appropriate biomarkers for quantification of
early changes.
• Difficulty in discriminating between temporary and
lasting health effects.
• Metabolic compensations for nutritional alterations.
Approaches
Four new approaches have emerged, which are worth
further development. These are described below, and pre-
sented in Fig. 2.
Biomarkers profile concept
Many of the established traditional risk markers or bio-
markers such as LDL-cholesterol, HDL-cholesterol,
triglycerides, glucose, homocysteine, IL-6, fibrinogen,
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Fig. 1 Differences between quantification of health and quantifica-
tion of disease. Although the change from health to disease can be
seen as a continuum, and thus the above discriminations should not be
regarded absolute, each of the indicated differences describes both the
difficulties encountered in quantification of health as well as the
opportunities for research direction
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Fig. 2 Some of the unique features of quantification of the nutritional
phenotype, as described above and presented in Fig. 1, are related to
the approaches presented in this paper
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serum amyloid A (SAA) and C-reactive protein (CRP)
were identified by classical epidemiology and their value
to predict future disease or future pathological events was
confirmed in large prospective cohorts [18, 26, 49]. Some
of these markers (e.g. LDL cholesterol or glucose) are not
only risk markers but can participate as risk factors in the
molecular processes that drive the disease development
they predict [30]. Such a clear pathological role has only
been established for a few of the risk markers that tra-
ditionally are used in the fields of medicine and nutrition.
For example, IL-6 can promote and retard the process of
atherosclerosis [28, 40, 56], and an active role of CRP, a
strong independent marker of future cardiovascular
events, is discussed controversially [48]. It is likely that
the high predictive power and the sensitivity of markers
such as CRP stems from their ability to integrate several
risk factors with a relatively short half life in plasma (i.e.
IL-1, IL-6 and TNFa in the case of CRP). [33, 47]. An
important drawback of those biomarkers that cannot be
mechanistically linked to a specific disease process is that
they often are not suitable for assessing or predicting
individual outcome, only that of a population. On the
other hand, a drawback of the biomarkers that actively
participate in the disease process is that they have only a
limited use in predicting an early stage of a disease:
once they are found to be elevated, the disease process
has already begun and it is often too late for a (mild)
intervention, for example by nutritional adjustments.
Therefore, and in particular for nutritional interventions,
novel biomarkers are necessary; (a) that can be used to
monitor the individual health status, and (b) that sense
future risk at a very early time point.
The recent developments in systems biology enable us to
accurately determine many metabolites, lipids and proteins
in plasma [63]. This technological improvement in combi-
nation with multivariate data analysis [57] provides new
opportunities to generate more comprehensive and com-
plete ‘biomarker profiles’ which allow us to better define
the individual health status, and to discriminate it from a
status that is associated with health risk [34]. Indeed recent
systems biology studies demonstrate that metabolomic
profiles (even at baseline) can capture characteristics of
early onset of disease, and may represent useful tools to
monitor nutritional intervention [37, 38]. Better assessment
of the phenotype of an individual will enable us to fine-tune
the classification of individuals, a topic of great relevance to
optimize nutritional as well as medical interventions. The
coming years will reveal whether multivariate biomarker
profiles, e.g. plasma fingerprints obtained by measuring a
multitude of parameters followed by sophisticated statisti-
cal analyses, are more powerful in detecting early changes
than the limited set of traditional individual biomarkers that
is used traditionally.
Biomarker profiles can be determined at the level of
metabolites including lipids, i.e. by applying powerful
state-of-the-art and standardized metabolomics and lipi-
domics which require only a few microliters of plasma
(\5 ll) or at the proteome or transcriptome level technol-
ogies [23, 37, 38, 44, 54, 72]. For example, the use of
peripheral blood mononuclear cells (PBMC) for genome-
wide gene expression analysis to identify biomarkers in
human intervention studies is currently being explored and
new omics-based biomarker sets appear to provide more
sensitive diagnostic tools for describing the nutritional
phenotype [9, 20, 21, 62]. This will enable us to discrim-
inate between healthy and unhealthy phenotypes more
effectively than classical approaches [1, 45]. Further
development of these novel tools and refinement of the
omics tools for the nutrigenomics research field will pro-
vide us with the opportunity to describe the more subtle
effects of the nutritional phenotype more accurately and
comprehensively along the line of recent biomarker pro-
filing concepts [8, 35, 54].
Perturbation of homeostasis
Maintaining homeostasis in a timely manner is essential for
optimal health. Early signs of homeostatic disturbance
as observed in onset of disease may be detected using
the biomarker profile approach described above, but in
describing nutritional effects on a healthy phenotype, the
very fact that we try to describe homeostasis limits the
power of this approach. To overcome these limits, challenge
tests are introduced in nutrition and health research [22].
These include variations of oral glucose and lipid tolerance
tests [68] organ function tests or exercise challenge [25].
Two important aspects addressed by challenge tests are:
• Nutrition-related disorders often arise from repeated
dietary challenges. For example, insulin resistance
arises from repeated metabolic challenges with
oxidative stress [14]. Understanding the molecular
physiology of dietary challenges, specifically compen-
satory, regulatory and damage-control mechanisms, in
terms of oxidative and inflammatory responses, might
lead to personalized enhancement or adaptation of
nutritional patterns.
• Challenging a system reveals weaknesses in metabolic
flexibility and robustness. Glucose tolerance tests, or
other functional tests, may provide more information on
metabolic status than static measurements (e.g. fasting
glucose).
Multiple regulatory systems are challenged simulta-
neously during dietary exposures, and do not react
independently. Thus, an integrated approach in quantifi-
cation of both the challenge and the response are needed.
Genes Nutr (2008) 3:51–59 53
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Omics technologies aid acquisition and processing of such
data.
Combining omics-based biomarkers with homeostatic
challenges may offer a second generation of omics-derived
early biomarkers of disease. Regardless, the multiple mea-
surements will provide detailed descriptions of the challenge
responses, enabling different aspects to be explored. For
example, pro- and anti-inflammatory response to a meta-
bolic challenge can be quantified based on the level of
classical measures such as C-reactive protein and interleu-
kins but also the time course of some 100 plasma proteins,
which can be quantified using multiplex approaches, tar-
geted metabolomics [70] or transcriptomics like analysis
of the complete leukocyte inflammation interactome [12].
This will require dealing with small signals (i.e. healthy
response), intermediate signals (i.e. pre-disease/sub-clinical
conditions) and strong signals (i.e. disease at different
stages). Complex biomarkers that take advantage of area-
under-the-curve measurements of organ responses to
specific challenges may provide tools for more sensitive
diagnostic nutritional phenotyping required for disease
prevention and dietary and lifestyle intervention.
Currently, there are significant limitations regarding the
commonly monitored parameters, used for assessment in
healthy people. For example, how can we measure non-
invasively the contribution of internal organs such as liver,
pancreas, visceral fat or small intestine and their contri-
bution to the nutritional phenotype? Mechanistic studies in
animal models will lead to markers, which offer organ-
specific nutritional phenotypic information (e.g. liver-spe-
cific protein secreted after a fatty acid challenge) or similar
diet-induced parameters.
Several options are available to enhance the resolution of
the nutritional assessment. One option is to increase the
power by using larger groups, but this is often difficult
especially in the initial stage of challenge approaches. As an
alternative it may be attractive to preselect a homogenous
(sub)group for the identification of effects and responses
and from there proceed to a larger population, using less
complicated and more focussed assessment procedures.
Another option is to intensify efforts in phenotyping. One
example is the use of non-invasive imaging (TD-NMR, see
also next paragraph) in animal studies to quantify the
amount lean mass over fat mass, which provides informa-
tion over time, rather than establishing this only at the
moment of sacrifice of the animal [58]. Intensifying phe-
notyping has two major advantages. First, it increases the
efficiency of establishing the relationship between molec-
ular change and phenotype. Second, it reduces the amount
of experimental animals and humans. Phenotyping can be
done by including behavioural assessments in nutrition
feeding studies. Behavioural aspects that can be studied in
animals include learning and memory using maze systems
and avoidance conditioning, motor function using grip
strength, rota rods and neurosensory performance using
acoustic and tactile startle responses. As an example,
dietary resveratrol was shown to induce molecular
changes leading to improved mitochondrial function, which
was supported by enhanced mitochondrial density and
functional assessment of mitochondrial respiration [41].
However, the relevance of the findings came from associ-
ated phenotyping, in particular from an endurance test
showing improved fitness [36].
Automation is an important aspect of phenotyping.
Passive transponders can be implanted in animals for con-
stant monitoring of temperature thus revealing small, but
significant differences in body temperature which would
otherwise remain unnoticed [29, 32]. Similarly, feeding,
drinking and movement can be monitored automatically not
only providing more accurate data, but also giving infor-
mation on periodicity. Presently, setups are available for
combined eating, drinking, x–y–z movement, activity (e.g.
running wheel), and calorimetric measurements (e.g.
http://www.colinst.com or http://www.TSE-systems.com).
The inclusion of this in nutritional studies will be a further
step towards characterization of the healthy phenotype.
While the above is detailed and exemplified for animals
studies, the same is obviously also relevant for human
studies, which would benefit from intensified phenotyping
in parallel to challenge studies and omic assessments.
Imaging
In addition to classical phenotypic descriptors in nutrition,
whole body imaging methods are essential; i.e. non-inva-
sive methods to assess the nutritional phenotype online
during challenge studies. These will support omics-driven
nutritional phenotyping with functional physiological area
under the curve (AUC) data sets. Nutrition research has
always been hampered by the inability to undertake
detailed analyses in vivo. Imaging offers a very powerful
tool, which allows real-time analysis in vivo, and new non-
invasive diagnostic concepts will develop into applications
that can subsequently be applied in medical diagnostics
(Table 1).
The already extensively applied X-ray technology has
been extremely helpful in detecting differences in tissue
densities like in bones. Computed tomography (CT) rep-
resents an advanced development of imaging based on a
large series of two-dimensional X-rays taken around a
single axis of rotation (tomos is Greek = slice) often
combined with injections of contrast agents of different
types. The images are digitally processed to create three-
dimensional images. Although X-rays can be used in
relation to nutritional questions this technology is often not
sensitive enough for most metabolic questions.
54 Genes Nutr (2008) 3:51–59
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Molecular imaging enables the visual representation,
characterization, and quantification of biological processes
at the cellular and subcellular levels within intact living
organisms [34, 41]. This approach offers distinct advantages
compared to more invasive methods. For example, molec-
ular imaging allows the visualization of the temporal as well
as the spatial regulation of a specific gene in a realistic
manner, keeping the dynamics of complex biological net-
works in an intact organism. Non-invasive imaging also
provides the possibility of repetitive assessments in the same
individual allowing the individual to serve as its own control.
Contag et al. [16] demonstrated for the first time that biolu-
minescence from luciferase encoded by the bacterial
luciferase gene could be detected in living mice. In their
study of mice infected with recombinant bacteria containing
the luciferase gene, the luminescence within the mice was
strong enough to be detected using an external light-sensitive
camera. It has subsequently been shown that transgenic
reporter mice with luciferase from firefly was readily
assessed non-invasively [17]. Blomhoff et al. have success-
fully used this luciferase imaging technique in nutrional
studies related to inflammation orchestrated via the essential
transcription factor NF-jB [6, 13]. There are now several
other detection methods to image gene expression in addition
to luciferase-mediated imaging.
The most promising of the new technologies are posi-
tron emission tomography (PET) [24], magnetic resonance
imaging (MRI) [65] and optical imaging using green
fluorescent protein [69] or near infra red fluorescence ([66]
which have been used to image in vivo gene regulation.
MRI spectroscopy (MRS) equipment can be tuned reg-
ister signals from nuclei like protons (H+), phosphorus,
sodium and fluorine. allows detection and assessment of
transfer, expression and subsequent intervention changes of
effectors or marker transgenes noninvasively in vivo [7].
‘‘Smart’’ MR contrast agents have been developed, making
it possible to change their conformational structure and
thereby induce MR-detectable changes. These agents are
‘‘activated’’ in response to physiological changes promoted
by biological reactions in cells, isolated organs and whole
animals. Similarly, MR spectroscopy is also used as a
noninvasive method to assess transgene expression indi-
rectly by means of MR-visible intracellular markers. These
markers take the form of intracellular endo/exogenous
metabolites associated with exogenous enzyme expression
and function. This technique is also applicable to many
different situations, from isolated cells to clinical imaging
of the whole body.
Positron emission tomography scanning is based on use
of positron emitting radioisotope (tracer), given into the
body on a biologically active molecule. The positron is also
called anti-electron and is the antiparticle of the electron.
The positron has a positive electrical charge with the same
mass as an electron. When a low-energy positron collides
with a low-energy electron, annihilation occurs, resulting
in the production of two gamma ray photons. 2-fluoro-2-
deoxy-D-glucose (abbreviated FDG) is a glucose derivative
with fluorine 18 (18F) is often used as isotope generating
gamma arrays. This isotope emits very small and only
temporary radioactivity and is used for describing uptake
and phosphorylation of glucose in different tissues. Images
of tracer concentration in 3-dimensional space are recon-
structed by data analysis. In modern scanners, this
reconstruction is often obtained by the aid of a CT X-ray or
MRI scanning performed on the subject during the same
PET session, in the same machine. Also other tracers than
FDG are used in PET scanning to image the tissue con-
centration or metabolism, like oxygen-15.
Table 1 Imaging techniques of interest in nutritional research
Type Abbreviation Principle Application
Ro¨ntgen array X-ray Different absorption of ionizing
radiation based on tissue density
Skeletal and dense inner
organs
Computed tomography CT or CAT scan Focused X-ray pictures in several
‘‘slices’’ computerized to 3D
images
Accurate imaging of organs
and tissues
Positron emission tomography PET Injected radio-tracers are detected
as gamma emitters
Detect blood flow,
metabolic changes
Magnetic resonance MR Charged molecules are realigned
in a strong and oscillating
magnetic field with different
rates
Soft tissues like adipose,
muscle, heart, joints can
be accurately quantified
Magnetic ressonance spectroscopy MRS MR combined with spectroscopy
of protons, phosphorus, sodium,
etc.
Linked to expression and
regulation of transgenes
Bioluminscence – Luciferase promotes light emission
upon activation
Detection of inflammatory
response caused by
supply of nutrients
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The MRI provides much greater soft tissue contrast
than CT. Unlike CT it uses no ionizing radiation, but a
strong magnetic field to align the nuclear magnetization
of charged molecules in the body. Radiofrequency fields
are used to alter the alignment of this magnetization,
causing the hydrogen nuclei (most often used) to produce
a rotating magnetic field detectable by the scanner. This
signal can be manipulated by additional magnetic fields
to build up enough information to reconstruct a 3D
image. MRI may be combined with angiography and CT
X-ray.
The MRI has been further developed including conju-
gates consisting of gene-targeting short nucleic acids
(oligodeoxynucleotides, or sODN) and superparamagnetic
iron oxide nanoparticles (SPION, and MR susceptibility
T2 agent) for reporting gene activity using transcription
MRI (tMRI; [39]). This method has been validated by the
correlations between results from conventional assays (in
situ hybridization, PCR, histology Prussian blue stain and
immunohistochemistry) in postmortem samples, and
retention of SPION-sODN using tMRI. Due to the rec-
ognition of nucleic acid sequences, tMRI probes with
complementary nucleic acid (antisense DNA or short
interfering RNA) allows tracking, targeting, binding to
intracellular mRNA, and manipulating gene action, in
addition to tracing cells with specific gene action in living
tissues. Transcription MRI may most likely be used for
many applications in living organs also related to
nutrition.
Modelling and fluxes
In quantifying health, the dynamic and kinetic aspects
should also be incorporated. This is partly addressed by
challenge tests (e.g. glucose or fat kinetics), but it can be
extended in many ways. For example, in vivo de novo
lipogenesis quantification by deuterated water flux analysis
[59] and lipoprotein biosynthesis and half-life by deuter-
ated leucine [1], both indicate how in vivo kinetics may
provide extra information in quantifying phenotypic effects
of nutrients.
Absorption patterns for micronutrients such as iron [55]
have been studied extensively using stable isotopes. In
essence, these data have been used to develop models of
absorption and of distribution within the organism. Some
studies have been carried out in different physiological
conditions (e.g. pregnancy) but they are difficult to set up
and analyse and interpretation is fraught with complica-
tions. A mathematical approach is currently being
developed and has been applied to other micronutrients
such as folate [46, 60]. These topics are further addressed
in review 4 in this series (systems biology approaches in
nutrition).
Towards a practical nutritional phenotype description
Many of the options described above are in the early stages
of development, and a major effort will be required before
we can hope to draw on meaningful omics-derived con-
clusions. As a priority, we need to understand homeostasis
not only in terms of relevant nutrigenomics data but also to
distinguish significant health markers from the background
noise, i.e. changes in gene expression, protein translation
and functionality, and metabolite concentrations. Early
agreement on a minimum set of parameters to be measured
in the majority of human nutritional studies would ease
comparison of results and establishment of a depository of
data for sharing. This requires extensive consensus as well
as provision of secure information systems.
One of the first steps towards this goal is to develop
systems that can capture accurately subtle changes in a
multitude of biological variables. This poses a substantial
challenge that requires standardized technology, method-
ology and data formats. Many lessons can be learned from
the mouse phenotyping community [3, 4, 27]. NuGO
(http://www.nugo.org) is currently building a set of online
tools, which could form the basis of nutritional phenotype
quantification, with the option to select, standardize, store
and query the relevant parameters. These elements are now
all centred around ‘‘NutriBASE’’, a laboratory information
management system (LIMS), which captures nutritional
studies with a strong omics component. NutriBase incor-
porates structured storage of nutritional metadata (i.e. study
design, treatments, phenotypic observations, etc.), enabling
subsequent detailed querying of datasets in databases.
Within the same database, transcriptomics (raw) data and
results can be stored and traced. NutriBASE is an extension
of BASE 2, an open source transcriptomics LIMS [51].
NutriBASE follows all current standards and exports to
public databases like ArrayExpress [50].
The NuGO developers and other collaborators are cur-
rently trying to extend this system to enable capture and
enhanced querying of all types of information, including
dietary intake, metabolomic and proteomic, (epi)genetic
and in vivo imaging data, with the ultimate goal of devel-
oping a nutritional phenotype database. It is envisaged that a
modular architecture will be employed for the different
components (study design and different data sets) as this not
only represents an efficient manner to store data but also
provides the flexibility to add extra modules to accommo-
date new technologies and all types of nutrition and health
research studies. The development will be carefully aligned
with other ongoing activities spanning different biological
sciences such as the EU Framework 7 Programme project
ELIXIR, which is coordinating the development of a new
European Life Sciences Infrastructure For Biological
Information (see http://www.elixir-europe.org). This is to
56 Genes Nutr (2008) 3:51–59
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avoid unnecessary replication and move more rapidly
towards universal standards.
Finally, of critical importance in the development of
nutritional phenotype databases is the need to develop
methods which integrate the biological and imaging data
with estimates of food and nutrient intake. At present, the
latter are hampered by the phenomenon of under-reporting
of food and nutrient intake and in this respect metabolomics
may have a role, not in the definitive analysis of the diets of
individuals but in allocating individuals to one of a number
of highly characterized metabolomic profiles. A second area
which will need attention to integrate omics with dietary
data will be the capacity to characterize dietary patterns
over a given time period in toto, rather than the present
system of the average intakes of individual foods or indi-
vidual nutrients. Radical new thinking in the collection,
analysis and presentation of dietary data is an imperative in
this area. This will be the topic of review nr 5 in this series.
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